You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The UK has given the go-ahead to a SARS-CoV-2 human challenge trial, Reuters reports.
University of Oxford researchers are investigating whether combining different COVID-19 vaccines provides the same or better protection than one type of vaccine alone, Business Insider says.
A new preprint reports Russia's Sputnik V vaccine is safe and effective against COVID-19, according to the Associated Press.
Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.
The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.
A monoclonal antibody treatment from Eli Lilly may slow the progression of Alzheimer's disease, the New York Times reports.
The test, called LifeKit Prevent, analyzes microbial genomic biomarkers in stool samples that are strongly associated with specific stages of CRC progression.
Novavax is launching a late-stage clinical trial of its prospective SARS-CoV-2 vaccine in the US and Mexico, according to the Financial Times.
Early trial data of a Sanofi and GlaxoSmithKline SARS-CoV-2 vaccine indicates an insufficient immune response among older participants, according to Reuters.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.